Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: Experience in a single hospital in Korea for 6.6 years

Journal of Korean Medical Science

Volumn 25, Issue 5, 2010, Pages 671-676

  Han, Seon Sook ^a   Yim, Jae Joon ^b   Yoo, Chul Gyu ^b   Kim, Young Whan ^b   Han, Sung Koo ^b   Shim, Young Soo ^b   Lee, Sang Min ^b  

^a Kangwon National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Candidiasis; Fungemia; Intensive care units; Mortality; Risk factors

Indexed keywords

ARTICLE; CANDIDIASIS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KOREA; LONGITUDINAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICS;

CANDIDIASIS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; KOREA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PILOT PROJECTS; RISK ASSESSMENT; RISK FACTORS;

EID: 77955296741     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.5.671     Document Type: Article

References (30)

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
2. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2007; 6: 21.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-5.
5. Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004; 25: 628-33.
6. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. Excess mortality, hospital stay, and cost due to candidemia: a case control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
7. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254-7.
8. Jamal WY, El-Din K, Rotimi VO, Chugh TD. An analysis of hospital-acquired bacteremia in intensive care unit patients in a university hospital in Kuwait. J Hosp Infect 1999; 43: 49-56.
9. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
10. Nieto-Rodriguez JA, Kusne S, Manez R, Irish W, Linden P, Magnone M, Wing EJ, Fung JJ, Starzl TE. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223: 70-6.
11. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
12. Nolla-Salas J, Stiges-Serra J, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
13. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J. Epidemiology, diagnosis, and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-16.
14. Herbrecht R. Managing the challenges of invasive fungal infections. Int J Antimicrob Agents 2006; 27 (Suppl 1): 1-2.
15. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
17. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-5.
18. Lee YH, Choi HJ, Lee MA. Risk factors for the development of nosocomial candidemia among patients in intensive care unit. Infect Chemother 2004; 36: 219-26.
19. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospitalacquired candidemia. The attributable mortality and excess length stay. Arch Intern Med 1998; 148: 2642-5.
20. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 2006; 27 (Suppl 1): 3-6.
21. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
22. Rolando N, Harvey F, Brahm J, Philpott-Haward J, Alexander G, Casewell M, Fagan E, Williams R. Fungal infection: a common, unrecognized complication of acute liver failure. J Hepatol 1991; 12: 1-9.
23. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996; 16: 389-402.
24. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28: 1187-90.
25. Fisher NC, Cooper MA, Hastings JG, Mutimer DJ. Fungal colonisation and fluconazole therapy in acute liver disease. Liver 1998; 18: 320-5.
26. Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc? receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331: 1122-8.
27. Guarner C, Runyon BA. Macrophage function in cirrhosis and the risk of bacterial infection. Hepatology 1995; 22: 367-9.
28. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal N, Thomsen AC, Garred P. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997; 40: 544-9.
29. Reisner BS, Woods GL. Times to detection of bacteria and yeasts in BACTEC 9240 blood culture bottles. J Clin Microbiol 1999; 37: 2024-6.
30. Saito T, Senda K, Takakura S, Fujihara N, Kudo T, Iinuma Y, Tanimoto M, Ichiyama S. Detection of bacteria and fungi in BacT/Alert standard blood-culture bottles. J Infect Chemother 2003; 9: 227-32.